Literature DB >> 2844467

Influence of age on the pharmacokinetics and pharmacodynamics of perindopril.

K R Lees1, S T Green, J L Reid.   

Abstract

Perindopril is the ester prodrug of the angiotensin converting enzyme inhibitor S-9780. The influence of age on the pharmacokinetics and pharmacodynamics of S-9780 (1 mg administered intravenously) and perindopril (8 mg administered orally) was examined in a double-blind, crossover, acute study in eight young (29 +/- 3 years) and eight elderly (71 +/- 3 years) healthy subjects. Mild headache and light-headedness were the only adverse effects and were more common in the younger subjects. Blood pressure fall was greater in the elderly even after correction for starting blood pressure. Bioavailability of S-9780 was increased in the elderly (35% +/- 17% compared with 19% +/- 7%; p less than 0.025) mainly because of increased conversion rather than absorption. Renal clearance of S-9780 was lower in the elderly (67 +/- 31 ml/min compared with 110 +/- 39 ml/min; p less than 0.03). Dose reduction of approximately 50% is suggested for elderly patients with further adjustment proportional to any preexisting diminished renal function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844467     DOI: 10.1038/clpt.1988.174

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  The pharmacokinetics of perindopril in patients with liver cirrhosis.

Authors:  M Thiollet; C Funck-Brentano; J D Grangé; M Midavaine; G Resplandy; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril.

Authors:  N J Macdonald; H L Elliott; D M Hughes; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding.

Authors:  K R Lees; A W Kelman; J L Reid; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

Review 5.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  Optimal dosage of ACE inhibitors in older patients.

Authors:  B Tomlinson
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

7.  Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril.

Authors:  L Alcocer; C Campos; J H Bahena; A Nacaud; J Parra Carillo; C Calvo; C Weber; G Lerebours; L Mickalonis; M T Villahermosa
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

8.  The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.

Authors:  H H Tsai; K R Lees; C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

Review 9.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

10.  Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.

Authors:  G A Verpooten; P M Genissel; J R Thomas; M E De Broe
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.